A new formulation of ellagic acid and pomegranate peel extract for dietary supplementation in an animal model of multiple sclerosis

My Ph.D. project was dedicated to evidentiate beneficial effects elicited by the therapeutic administration of a new formulation of ellagic acid (Ellagic Acid microdispersion, EAm) and pomegranate peel extract (Pomegranate peel Extract microdispersion, PEm) in an animal model of multiple sclerosis (the EAE mice), with particular attention to its impact on “in vivo” and “in vitro” parameters at the acute stage of disease, to support its translation to clinical studies in patients suffering from multiple sclerosis. My thesis was composed of two different sections: the first one focuses on the characterization of the EAE model and the analysis of the healthy properties of the formulations on it; the second one investigates a potential therapeutic target of ellagic acid. The study led to two recent publications in Molecules and Antioxidants and was exposed in the poster section of national and international congresses reported in the last part of the thesis. The thesis would also briefly describe other studies I was involved in during the 3 years Ph.D. program.